Wednesday, November 22, 2017

FDA: Potentially Life-Threatening Adverse Events Linked to Limbrel

Monthly Prescribing Reference-6 hours ago
The Food and Drug Administration (FDA) has issued an advisory regarding serious adverse events linked to the medical food Limbrel (flavocoxid; Primus). Limbrel is indicated for the dietary management of the metabolic processes associated with osteoarthritis, and is available in 250mg and 500mg strength capsules.

No comments: